Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.53 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL970515 | 1.00 | MAPT (0.59) | MAPTGPR84FFAR1LCKPPARD | |
| SCHEMBL7207894 | 1.00 | MAPT (0.59) | MAPTGPR84FFAR1LCKPPARD | |
| SCHEMBL10923278 | 1.00 | MAPT (0.59) | MAPTGPR84FFAR1LCKPPARD | |
| SCHEMBL4002470 | 1.00 | MAPT (0.59) | MAPTGPR84FFAR1LCKPPARD | |
| SCHEMBL6539103 | 0.98 | MAPT (0.55) | MAPTGPR84FFAR1LCKPPARD | |
| SCHEMBL1401236 | 0.91 | CA2 (0.50) | MAPTGPR84FFAR1LCKPPARD | |
| SCHEMBL5158482 | 0.83 | MAPT (0.48) | MAPTGPR84FFAR1LCKPPARD | |
| SCHEMBL11329644 | 0.83 | MAPT (0.48) | MAPTGPR84FFAR1LCKPPARD | |
| SCHEMBL8458707 | 0.83 | MAPT (0.48) | MAPTGPR84FFAR1LCKPPARD | |
| SCHEMBL3127134 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 423 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3065767-B1 | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA AS (DK) | 2020-12-30 | — | — | EP | claimed |
| US-20190218270-A1 | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2019-07-18 | — | — | US | claimed |
| US-20160280754-A1 | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2016-09-29 | — | — | US | claimed |
| EP-3065767-A2 | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS | Zealand Pharma A/S (DK) | 2016-09-14 | — | — | EP | claimed |
| WO-2015067715-A2 | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA A/S (DK) | 2015-05-14 | — | — | WO | claimed |
| EP-1517697-A1 | ACIDIC INSULIN PREPARATIONS WITH IMPROVED STABILITY | Aventis Pharma Deutschland GmbH (DE) | 2005-03-30 | — | — | EP | claimed |
| EP-1381385-A1 | INSULIN PREPARATIONS, WHICH DO NOT CONTAIN ANY ZINC OR ONLY A SMALL QUANTITY OF ZINC AND WHICH HAVE AN IMPROVED STABILITY | Aventis Pharma Deutschland GmbH (DE) | 2004-01-21 | — | — | EP | claimed |
| WO-2003105888-A1 | ACIDIC INSULIN PREPARATIONS WITH IMPROVED STABILITY | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-24 | — | — | WO | claimed |
| WO-2002076495-A1 | INSULIN PREPARATIONS, WHICH DO NOT CONTAIN ANY ZINC OR ONLY A SMALL QUANTITY OF ZINC AND WHICH HAVE AN IMPROVED STABILITY | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-03 | — | — | WO | claimed |
| EP-1121145-A1 | INSULIN PREPARATIONS FOR PULMONARY DELIVERY CONTAINING MENTHOL | Novo Nordisk A/S (DK) | 2001-08-08 | — | — | EP | claimed |
| EP-1121144-A1 | STABLE CONCENTRATED INSULIN PREPARATIONS FOR PULMONARY DELIVERY | Novo Nordisk A/S (DK) | 2001-08-08 | — | — | EP | claimed |
| WO-2000023099-A1 | INSULIN PREPARATIONS FOR PULMONARY DELIVERY CONTAINING MENTHOL | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | claimed |
| WO-2000023098-A1 | STABLE CONCENTRATED INSULIN PREPARATIONS FOR PULMONARY DELIVERY | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | claimed |
| EP-4297830-A1 | FLUID DISPENSING DEVICE | Sanofi (FR) | 2024-01-03 | — | — | EP | disclosed |
| EP-4252248-A1 | CLASSIFYING IMAGES OF DOSE-RESPONSE GRAPHS | Sanofi (FR) | 2023-10-04 | — | — | EP | disclosed |
| EP-4222756-A1 | METHODS AND SYSTEMS FOR TRACKING DOSAGE INFORMATION OF ELECTRONICALLY ENABLED INJECTION DEVICES | Sanofi (FR) | 2023-08-09 | — | — | EP | disclosed |
| EP-0969860-A1 | METHOD FOR PREPARATION OF A THERAPEUTIC POWDER THROUGH COPRECIPITATION OF INSULIN AND ABSORPTION ENHANCER | NOVO NORDISK A/S (DK) | 2000-01-12 | — | — | EP | disclosed |
| WO-1999034821-A1 | STABILISED INSULIN COMPOSITIONS | NOVO NORDISK A/S (DK) | 1999-07-15 | — | — | WO | disclosed |
| WO-1998042367-A1 | METHOD FOR PREPARATION OF A THERAPEUTIC POWDER THROUGH COPRECIPITATION OF INSULIN AND ABSORPTION ENHANCER | NOVO NORDISK A/S (DK) | 1998-10-01 | — | — | WO | disclosed |
| WO-1998042368-A1 | THERAPEUTIC POWDER FORMULATION FOR PULMONARY ADMINISTRATION, CONTAINING CRYSTALLINE INSULIN | NOVO NORDISK A/S (DK) | 1998-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280754-A1 | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS | GLP1R, GIPR, GCGR | MAPT 4780/4885GPR84 100/4885FFAR1 142/4885 |
| US-20190218270-A1 | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS | GLP1R, GIPR, GCGR | MAPT 4780/4885GPR84 100/4885FFAR1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.